ReShape Lifesciences Inc. (RSLS)

Market Cap	3.12M
Revenue (ttm)	8.18M
Net Income (ttm)	-7.07M
Shares Out	712.68K
EPS (ttm)	-17.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,463
Open	4.380
Previous Close	4.400
Day's Range	4.275 - 4.690
52-Week Range	4.090 - 29.000
Beta	1.38
Analysts	Hold
Price Target	n/a
Earnings Date	Nov 14, 2024

About RSLS

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual’s comfort and therapy effec...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 15, 2007
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: RSLS
• Website: https://www.reshapelifesciences.com

Financial Performance

In 2023, ReShape Lifesciences's revenue was $8.68 million, a decrease of -22.79% compared to the previous year's $11.24 million. Losses were -$11.39 million, -75.36% less than in 2022.